Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS

@inproceedings{Hodecker2017MaravirocAP,
  title={Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS},
  author={Sibylle C. Hodecker and Klarissa Hanja St{\"u}rner and Veit Becker and Birte Elias-Hamp and Brigitte Holst and Manuel A Friese and Christoph Heesen},
  booktitle={Neurology(R) neuroimmunology & neuroinflammation},
  year={2017}
}
Progressive multifocal leukoencephalopathy (PML) is a serious complication of natalizumab treatment in patients with relapsing-remittingMS (RRMS) with 638 confirmed cases as of March 2016. Therapeutic reestablishment of cerebral immune surveillance in PML management is complicated by immune reconstitution inflammatory syndrome (IRIS), an exuberant inflammatory response that aggravates damage caused by John Cunningham virus (JCV) infection and ultimately leads to a combined PML/IRIS syndrome… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 37 times over the past 90 days. VIEW TWEETS

Similar Papers

Loading similar papers…